FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965929829> ?p ?o ?g. }

• W1965929829 endingPage "131" @default.
• W1965929829 startingPage "126" @default.
• W1965929829 abstract "Background & Aims Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC). Metronomic chemotherapy using tegafur/uracil (4:1 molar ratio), an oral fluoropyrimidine, has been shown to enhance the anti-tumor effect of anti-angiogenic agents in preclinical models. This phase II study evaluated the efficacy and safety of combining metronomic tegafur/uracil with sorafenib in patients with advanced HCC. Methods Patients with histologically- or cytologically-proven HCC and Child-Pugh class A liver function were treated with sorafenib (400 mg twice daily) and tegafur/uracil (125 mg/m2 based on tegafur twice daily) continuously as first-line therapy for metastatic or locally advanced disease that could not be treated by loco-regional therapies. The primary endpoint was progression-free survival (PFS). Results The study enrolled 53 patients. Thirty-eight patients (72%) were hepatitis B surface antigen-positive. The median PFS was 3.7 months (95% C.I., 1.9–5.5) and the median overall survival was 7.4 months (95% C.I., 3.4–11.4). According to RECIST criteria, 4 patients (8%) had a partial response and 26 patients (49%) had a stable disease. Major grade 3/4 toxicities included fatigue (15%), abnormal liver function (13%), elevated serum lipase (10%) hand-foot skin reaction (HFSR) (9%), and bleeding (8%). HFSR was the major adverse event resulting in dose reduction (19%) or treatment delay (21%). Conclusions Metronomic chemotherapy with tegafur/uracil can be safely combined with sorafenib and shows preliminary activity to improve the efficacy of sorafenib in advanced HCC patients. Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC). Metronomic chemotherapy using tegafur/uracil (4:1 molar ratio), an oral fluoropyrimidine, has been shown to enhance the anti-tumor effect of anti-angiogenic agents in preclinical models. This phase II study evaluated the efficacy and safety of combining metronomic tegafur/uracil with sorafenib in patients with advanced HCC. Patients with histologically- or cytologically-proven HCC and Child-Pugh class A liver function were treated with sorafenib (400 mg twice daily) and tegafur/uracil (125 mg/m2 based on tegafur twice daily) continuously as first-line therapy for metastatic or locally advanced disease that could not be treated by loco-regional therapies. The primary endpoint was progression-free survival (PFS). The study enrolled 53 patients. Thirty-eight patients (72%) were hepatitis B surface antigen-positive. The median PFS was 3.7 months (95% C.I., 1.9–5.5) and the median overall survival was 7.4 months (95% C.I., 3.4–11.4). According to RECIST criteria, 4 patients (8%) had a partial response and 26 patients (49%) had a stable disease. Major grade 3/4 toxicities included fatigue (15%), abnormal liver function (13%), elevated serum lipase (10%) hand-foot skin reaction (HFSR) (9%), and bleeding (8%). HFSR was the major adverse event resulting in dose reduction (19%) or treatment delay (21%). Metronomic chemotherapy with tegafur/uracil can be safely combined with sorafenib and shows preliminary activity to improve the efficacy of sorafenib in advanced HCC patients." @default.
• W1965929829 created "2016-06-24" @default.
• W1965929829 creator A5003833817 @default.
• W1965929829 creator A5017953971 @default.
• W1965929829 creator A5033582283 @default.
• W1965929829 creator A5045902068 @default.
• W1965929829 creator A5058253583 @default.
• W1965929829 creator A5059267212 @default.
• W1965929829 creator A5066591690 @default.
• W1965929829 creator A5090591171 @default.
• W1965929829 date "2010-07-01" @default.
• W1965929829 modified "2023-10-15" @default.
• W1965929829 title "Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma" @default.
• W1965929829 cites W1604740730 @default.
• W1965929829 cites W1971837077 @default.
• W1965929829 cites W1984750597 @default.
• W1965929829 cites W1991512467 @default.
• W1965929829 cites W1994193851 @default.
• W1965929829 cites W2009938692 @default.
• W1965929829 cites W2022169488 @default.
• W1965929829 cites W2029883816 @default.
• W1965929829 cites W2048601055 @default.
• W1965929829 cites W2048829586 @default.
• W1965929829 cites W2074470232 @default.
• W1965929829 cites W2075549113 @default.
• W1965929829 cites W2078429942 @default.
• W1965929829 cites W2080663543 @default.
• W1965929829 cites W2081704237 @default.
• W1965929829 cites W2111489144 @default.
• W1965929829 cites W2114029473 @default.
• W1965929829 cites W2133832832 @default.
• W1965929829 cites W2139248078 @default.
• W1965929829 cites W2140765540 @default.
• W1965929829 cites W2156871508 @default.
• W1965929829 cites W2164653269 @default.
• W1965929829 cites W2169965478 @default.
• W1965929829 cites W2591170673 @default.
• W1965929829 cites W310150161 @default.
• W1965929829 cites W4243625103 @default.
• W1965929829 cites W4250975909 @default.
• W1965929829 doi "https://doi.org/10.1016/j.jhep.2010.01.035" @default.
• W1965929829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20416968" @default.
• W1965929829 hasPublicationYear "2010" @default.
• W1965929829 type Work @default.
• W1965929829 sameAs 1965929829 @default.
• W1965929829 citedByCount "117" @default.
• W1965929829 countsByYear W19659298292012 @default.
• W1965929829 countsByYear W19659298292013 @default.
• W1965929829 countsByYear W19659298292014 @default.
• W1965929829 countsByYear W19659298292015 @default.
• W1965929829 countsByYear W19659298292016 @default.
• W1965929829 countsByYear W19659298292017 @default.
• W1965929829 countsByYear W19659298292018 @default.
• W1965929829 countsByYear W19659298292019 @default.
• W1965929829 countsByYear W19659298292020 @default.
• W1965929829 countsByYear W19659298292021 @default.
• W1965929829 countsByYear W19659298292023 @default.
• W1965929829 crossrefType "journal-article" @default.
• W1965929829 hasAuthorship W1965929829A5003833817 @default.
• W1965929829 hasAuthorship W1965929829A5017953971 @default.
• W1965929829 hasAuthorship W1965929829A5033582283 @default.
• W1965929829 hasAuthorship W1965929829A5045902068 @default.
• W1965929829 hasAuthorship W1965929829A5058253583 @default.
• W1965929829 hasAuthorship W1965929829A5059267212 @default.
• W1965929829 hasAuthorship W1965929829A5066591690 @default.
• W1965929829 hasAuthorship W1965929829A5090591171 @default.
• W1965929829 hasConcept C126322002 @default.
• W1965929829 hasConcept C141071460 @default.
• W1965929829 hasConcept C143998085 @default.
• W1965929829 hasConcept C197934379 @default.
• W1965929829 hasConcept C2776694085 @default.
• W1965929829 hasConcept C2777299880 @default.
• W1965929829 hasConcept C2778019345 @default.
• W1965929829 hasConcept C2778695046 @default.
• W1965929829 hasConcept C2778822529 @default.
• W1965929829 hasConcept C2779984678 @default.
• W1965929829 hasConcept C2992208098 @default.
• W1965929829 hasConcept C71924100 @default.
• W1965929829 hasConcept C90924648 @default.
• W1965929829 hasConceptScore W1965929829C126322002 @default.
• W1965929829 hasConceptScore W1965929829C141071460 @default.
• W1965929829 hasConceptScore W1965929829C143998085 @default.
• W1965929829 hasConceptScore W1965929829C197934379 @default.
• W1965929829 hasConceptScore W1965929829C2776694085 @default.
• W1965929829 hasConceptScore W1965929829C2777299880 @default.
• W1965929829 hasConceptScore W1965929829C2778019345 @default.
• W1965929829 hasConceptScore W1965929829C2778695046 @default.
• W1965929829 hasConceptScore W1965929829C2778822529 @default.
• W1965929829 hasConceptScore W1965929829C2779984678 @default.
• W1965929829 hasConceptScore W1965929829C2992208098 @default.
• W1965929829 hasConceptScore W1965929829C71924100 @default.
• W1965929829 hasConceptScore W1965929829C90924648 @default.
• W1965929829 hasIssue "1" @default.
• W1965929829 hasLocation W19659298291 @default.
• W1965929829 hasLocation W19659298292 @default.
• W1965929829 hasOpenAccess W1965929829 @default.
• W1965929829 hasPrimaryLocation W19659298291 @default.
• W1965929829 hasRelatedWork W1584669207 @default.

• next